HOSPITAL FOR SPECIAL SURGERY
- Type
- Teaching hospital
- Where
- New York, NY
- Medicare CCN
- 330270
- Received
- $3,770,906 in 327 records, 2022 ($1,964,693 general, $1,806,213 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: HOSPITAL FOR SPECIAL SURGERY Fuzzy (name and state)
- Lobbying client: HOSPITAL FOR SPECIAL SURGERY Fuzzy (name and state)
- Lobbying client: HOSPITAL FOR SPECIAL SURGERY Fuzzy (name and state)
- Lobbying client: HOSPITAL FOR SPECIAL SURGERY Fuzzy (name and state)
- Lobbying client: HOSPITAL FOR SPECIAL SURGERY Fuzzy (name and state)
- Patent assignee: Hospital for Special Surgery Fuzzy (name and state)
- Trademark owner: Hospital for Special Surgery Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2022 | General payment | 145 | $1,964,693 |
| 2022 | Research payment | 182 | $1,806,213 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 182 | $1,806,213 |
| Space rental or facility fees (teaching hospital only) | 56 | $830,257 |
| Royalty or License | 16 | $601,675 |
| Grant | 42 | $454,996 |
| Debt forgiveness | 7 | $43,788 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 8 | $16,040 |
| Consulting Fee | 2 | $11,000 |
| Education | 1 | $5,877 |
| Long term medical supply or device loan | 13 | $1,057 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | Siemens Medical Solutions USA, Inc. | $4,500 | Research payment | In-kind items and services | HSSPotterMSKClinicalMR2021 | 2022 | |
| 2022-12-31 | AstraZeneca UK Limited | $3,309 | Research payment | In-kind items and services | SAPHNELO Biological, Inflammation and Autoimmunity | The purpose of this study is to characterise longterm safety and tolerability of intravenous anifrolumab A Multicentre R | 2022 |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | $2,544 | Research payment | In-kind items and services | FASENRA Biological, Respiratory | A Randomised, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Sa | 2022 |
| 2022-12-31 | Stryker Corporation | $1,351 | Debt forgiveness | Cash or cash equivalent | 2022 | ||
| 2022-12-31 | ABBVIE INC. | $1,092 | Research payment | In-kind items and services | A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM | 2022 | |
| 2022-12-29 | UOC USA INC | $3,575 | Consulting Fee | Cash or cash equivalent | U-Motion II Device, United Hip System | 2022 | |
| 2022-12-21 | Medical Device Business Services, Inc. | $154,035 | Research payment | Cash or cash equivalent | MOUNTAINEER Device, Spine | 2022 | |
| 2022-12-21 | ABBVIE INC. | $34 | Research payment | Cash or cash equivalent | A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM | 2022 | |
| 2022-12-20 | Smith+Nephew, Inc. | $10,137 | Debt forgiveness | Cash or cash equivalent | DYONICS / BONECUTTER Device, Sports Med Resection | 2022 | |
| 2022-12-20 | Smith+Nephew, Inc. | $540 | Research payment | Cash or cash equivalent | OR3O Dual Mobility Device, Recon Hips | Prospective Multi-Center study to evaluate the safety and effectiveness of the OR30 Dual Mobility system in primary and | 2022 |
| 2022-12-16 | Stryker Corporation | $28,666 | Research payment | Cash or cash equivalent | RIO Device, ROBOTICS | SURVIVORSHIP AND OUTCOMES OF ROBOTIC ARM ASSISTED MEDIAL UKA | 2022 |
| 2022-12-15 | Medical Device Business Services, Inc. | $10,000 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-12-15 | Ortho Development Corporation | $180 | Royalty or License | Cash or cash equivalent | Pagoda Device, ORTHOPEDIC DEVICE | 2022 | |
| 2022-12-15 | Smith+Nephew, Inc. | $67 | Research payment | Cash or cash equivalent | SPATIAL FRAME Device, Sports Med Knee | A Prospective, Multi-Center Clinical Study to Evaluate the Safety and Performance of the Fast-Fix Flex System for Menisc | 2022 |
| 2022-12-14 | ABBVIE INC. | $5,594 | Research payment | Cash or cash equivalent | A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM | 2022 | |
| 2022-12-09 | Stryker Corporation | $20,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | MAKO Device, KNEES, HIPS | 2022 | |
| 2022-12-09 | ARGENX US, INC. | $500 | Research payment | Cash or cash equivalent | A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chr | 2022 | |
| 2022-12-08 | Heron Therapeutics, Inc. | $12,000 | Research payment | Cash or cash equivalent | SUSTOL Drug, CINV | Safety Study of Repeat Doses of SUSTOL in Adults | 2022 |
| 2022-12-08 | Zimmer Biomet Holdings, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Persona Device, Knees | 2022 | |
| 2022-12-01 | Lima USA, Inc. | $32,076 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Promade Device, Devices | 2022 | |
| 2022-12-01 | Zimmer Biomet Holdings, Inc. | $7,272 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Persona Device, Knees | 2022 | |
| 2022-12-01 | TREACE MEDICAL CONCEPTS, INC. | $4,461 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LAPIPLASTY SYSTEM Device, FOOT AND ANKLE | 2022 | |
| 2022-11-30 | Orthofix Medical, Inc. | $6,585 | Research payment | Cash or cash equivalent | M6-C Device, Prosthesis, Intervertebral Disc | M6-C Artificial Cervical Disc IDE Post Approval Study | 2022 |
| 2022-11-29 | Smith+Nephew, Inc. | $1,755 | Research payment | Cash or cash equivalent | BIRMINGHAM HIP Device, Recon Hips | A Post-Approval Study of the Birmingham Hip Resurfacing (BHR) Radiological System Review | 2022 |
| 2022-11-29 | Smith+Nephew, Inc. | $67 | Research payment | Cash or cash equivalent | SPATIAL FRAME Device, Sports Med Knee | A Prospective, Multi-Center Clinical Study to Evaluate the Safety and Performance of the Fast-Fix Flex System for Menisc | 2022 |
| 2022-11-25 | Stryker Corporation | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ACCOLADE Device, HIPS | 2022 | |
| 2022-11-24 | Takeda Pharmaceuticals U.S.A., Inc. | $2,603 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2022 |
| 2022-11-23 | Orthofix Medical, Inc. | $13,171 | Research payment | Cash or cash equivalent | M6-C Device, Prosthesis, Intervertebral Disc | M6-C Artificial Cervical Disc IDE Post Approval Study | 2022 |
| 2022-11-21 | SANOFI US SERVICES INC. | $1,674 | Research payment | Cash or cash equivalent | An Open Label, Two-Arm Study to Evaluate the Effect of Rilzabrutinib (PRN1008) on Safety and Disease Activity in Patient | 2022 | |
| 2022-11-18 | Medtronic, Inc. | $50,000 | Research payment | Cash or cash equivalent | Medical Device Directive/Up-class | 2022 | |
| 2022-11-18 | Smith+Nephew, Inc. | $26,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | TAYLOR SPATIAL FRAME Device, Extremities & Limb Restoration | 2022 | |
| 2022-11-15 | Ortho Development Corporation | $356 | Royalty or License | Cash or cash equivalent | Pagoda Device, ORTHOPEDIC DEVICE | 2022 | |
| 2022-11-10 | Smith+Nephew, Inc. | $7,485 | Research payment | Cash or cash equivalent | OR3O Dual Mobility Device, Recon Hips | Prospective Multi-Center study to evaluate the safety and effectiveness of the OR30 Dual Mobility system in primary and | 2022 |
| 2022-11-10 | SI-BONE, INC. | $4,725 | Research payment | Cash or cash equivalent | IFUSE IMPLANT Device, SACROILIAC JOINT DYSFUNCTION | SILVIA | 2022 |
| 2022-11-10 | Zimmer Biomet Holdings, Inc. | $1,500 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-11-09 | ABBVIE INC. | $4,472 | Research payment | Cash or cash equivalent | A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM | 2022 | |
| 2022-11-07 | Smith+Nephew, Inc. | $15,000 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-11-07 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,842 | Research payment | Cash or cash equivalent | OFEV Drug, RESPIRATORY | Extension | 2022 |
| 2022-11-03 | Novartis Pharmaceuticals Corporation | $163,544 | Research payment | Cash or cash equivalent | A TWO-YEAR, PHASE III RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY, EFFICAC | 2022 | |
| 2022-11-03 | Zimmer Biomet Holdings, Inc. | $10,000 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-11-03 | Stryker Corporation | $291 | Research payment | Cash or cash equivalent | TRITANIUM Device, HIPS | TRIDENT II TRITANIUM OUTCOMES STUDY | 2022 |
| 2022-11-02 | AMAG Pharmaceuticals, Inc. | $4,215 | Research payment | Cash or cash equivalent | FERAHEME Drug, For the treatment of iron deficiency anemia associated with chronic kidney disease | Efficacy and Safety of Low-Dose Ferumoxytol for Vascular Suppression in Magnetic Resonance Neurography (MRN) | 2022 |
| 2022-11-02 | SANOFI US SERVICES INC. | $3,422 | Research payment | Cash or cash equivalent | An Open Label, Two-Arm Study to Evaluate the Effect of Rilzabrutinib (PRN1008) on Safety and Disease Activity in Patient | 2022 | |
| 2022-11-01 | Lima USA, Inc. | $32,076 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Promade Device, Devices | 2022 | |
| 2022-10-31 | Medical Device Business Services, Inc. | $1,335 | Research payment | Cash or cash equivalent | Kincise Device, Ortho-Hip | Prospective Randomized Multi Center Post Market study of Anterior Advantage Surgical Approach in Total Hip Arthroplasty | 2022 |
| 2022-10-27 | Medtronic, Inc. | $11,954 | Research payment | Cash or cash equivalent | MAZOR X SYSTEM Device, Image Guided Surgery Products | Investigator Sponsored Research | 2022 |
| 2022-10-27 | Stryker Corporation | $2,000 | Research payment | Cash or cash equivalent | ACCOLADE Device, HIPS | METAL ION LEVELS IN STRYKER TRIDENT II TRITANIUM SYSTEM WITH MDM LINER, CERAMIC HEAD, AND ACCOLADE II OR SECURFIT ADVANC | 2022 |
| 2022-10-27 | Stryker Corporation | $2,000 | Research payment | Cash or cash equivalent | TRIATHLON Device, KNEES | MAVRIC MAGNETIC RESONANCE IMAGING USED TO STUDY DETAILED BONE APPOSITION AND FIXATION OF THE STRYKER TRIATHLON CEMENTLES | 2022 |
| 2022-10-27 | Stryker Corporation | $141 | Research payment | Cash or cash equivalent | INFINITY Device, TRAUMA & EXTREMITIES | INFINITY WITH ADAPTIS TECHNOLOGY TOTAL ANKLE REPLACEMENT FOLLOW-UP (ITAR2) | 2022 |
| 2022-10-25 | Medtronic, Inc. | $7,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-10-20 | Novartis Pharmaceuticals Corporation | $14,910 | Research payment | Cash or cash equivalent | A RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO CONTROLLED MULTICENTER PHASE III TRIAL TO INVESTIGATE THE EFFICACY A | 2022 | |
| 2022-10-20 | E.R. Squibb & Sons, L.L.C. | $13,902 | Research payment | Cash or cash equivalent | ORENCIA Biological, Immunology | Analysis of T and B Cell Repertoire Changes and CTLA4 Genetics and Gene Expression to Understand the Mechanisms of Treat | 2022 |
| 2022-10-20 | Stryker Corporation | $1,360 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-10-19 | ABBVIE INC. | $34 | Research payment | Cash or cash equivalent | A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM | 2022 | |
| 2022-10-17 | Pacira Pharmaceuticals Incorporated | $15,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Iovera Device, Pain Management | 2022 | |
| 2022-10-14 | Medical Device Business Services, Inc. | $5,687 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-10-14 | Ortho Development Corporation | $1,663 | Royalty or License | Cash or cash equivalent | Pagoda Device, ORTHOPEDIC DEVICE | 2022 | |
| 2022-10-13 | Zimmer Biomet Holdings, Inc. | $20,000 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-10-13 | ABBVIE INC. | $7,690 | Research payment | Cash or cash equivalent | A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM | 2022 | |
| 2022-10-12 | Smith+Nephew, Inc. | $13,128 | Research payment | Cash or cash equivalent | SPATIAL FRAME Device, Sports Med Knee | A Prospective, Multi-Center Clinical Study to Evaluate the Safety and Performance of the Fast-Fix Flex System for Menisc | 2022 |
| 2022-10-12 | Smith+Nephew, Inc. | $335 | Research payment | Cash or cash equivalent | SPATIAL FRAME Device, Sports Med Knee | A Prospective, Multi-Center Clinical Study to Evaluate the Safety and Performance of the Fast-Fix Flex System for Menisc | 2022 |
| 2022-10-12 | Smith+Nephew, Inc. | $133 | Research payment | Cash or cash equivalent | SPATIAL FRAME Device, Sports Med Knee | A Prospective, Multi-Center Clinical Study to Evaluate the Safety and Performance of the Fast-Fix Flex System for Menisc | 2022 |
| 2022-10-10 | ILLUMINOSS MEDICAL, INC. | $5,877 | Education | Cash or cash equivalent | Photodynamic Bone Stabilization Procedure Pack Device, Orthopedic | 2022 | |
| 2022-10-05 | Lima USA, Inc. | $41,387 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Promade Device, Devices | 2022 | |
| 2022-10-05 | AMAG Pharmaceuticals, Inc. | $2,810 | Research payment | Cash or cash equivalent | FERAHEME Drug, For the treatment of iron deficiency anemia associated with chronic kidney disease | Efficacy and Safety of Low-Dose Ferumoxytol for Vascular Suppression in Magnetic Resonance Neurography (MRN) | 2022 |
| 2022-10-03 | Takeda Pharmaceuticals U.S.A., Inc. | $2,301 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | LONG-TERM TOLERABILITY AND SAFETY OF IMMUNE GLOBULIN INFUSION 10% (HUMAN) WITH RECOMBINANT HUMAN HYALURONIDASE (HYQVIA/H | 2022 |
| 2022-10-03 | Takeda Pharmaceuticals U.S.A., Inc. | $1,450 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | LONG-TERM TOLERABILITY AND SAFETY OF IMMUNE GLOBULIN INFUSION 10% (HUMAN) WITH RECOMBINANT HUMAN HYALURONIDASE (HYQVIA/H | 2022 |
| 2022-10-03 | Takeda Pharmaceuticals U.S.A., Inc. | $1,450 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | LONG-TERM TOLERABILITY AND SAFETY OF IMMUNE GLOBULIN INFUSION 10% (HUMAN) WITH RECOMBINANT HUMAN HYALURONIDASE (HYQVIA/H | 2022 |
| 2022-10-03 | Takeda Pharmaceuticals U.S.A., Inc. | $784 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | LONG-TERM TOLERABILITY AND SAFETY OF IMMUNE GLOBULIN INFUSION 10% (HUMAN) WITH RECOMBINANT HUMAN HYALURONIDASE (HYQVIA/H | 2022 |
| 2022-10-03 | Takeda Pharmaceuticals U.S.A., Inc. | $50 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | LONG-TERM TOLERABILITY AND SAFETY OF IMMUNE GLOBULIN INFUSION 10% (HUMAN) WITH RECOMBINANT HUMAN HYALURONIDASE (HYQVIA/H | 2022 |
| 2022-10-01 | Lima USA, Inc. | $32,076 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Promade Device, Devices | 2022 | |
| 2022-09-30 | EXACTECH, INC. | $117,309 | Royalty or License | Cash or cash equivalent | TRULIANT Device, ORTHOPAEDIC | 2022 | |
| 2022-09-30 | CSL Behring | $2,025 | Research payment | Cash or cash equivalent | Hizentra Biological, Immunology | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2022 |
| 2022-09-30 | CSL Behring | $730 | Research payment | Cash or cash equivalent | Hizentra Biological, Immunology | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2022 |
| 2022-09-28 | UOC USA INC | $7,425 | Consulting Fee | Cash or cash equivalent | U-Motion II Device, United Hip System | 2022 | |
| 2022-09-28 | Alexion Pharmaceuticals, Inc. | $3,274 | Research payment | Cash or cash equivalent | ULTOMIRIS Biological, Rare Disease | Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Co | 2022 |
| 2022-09-26 | UCB SA | $1,050 | Research payment | Cash or cash equivalent | A RANDOMIZED, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF ROZANOLIXIZU | 2022 | |
| 2022-09-23 | Alexion Pharmaceuticals, Inc. | $13,900 | Research payment | Cash or cash equivalent | ULTOMIRIS Biological, Rare Disease | A Phase 2 3, Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy an | 2022 |
| 2022-09-21 | Medtronic, Inc. | $10,585 | Research payment | Cash or cash equivalent | MAZOR X SYSTEM Device, Image Guided Surgery Products | Investigator Sponsored Research | 2022 |
| 2022-09-21 | Synthes GmbH | $6,500 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-09-21 | AMAG Pharmaceuticals, Inc. | $2,242 | Research payment | Cash or cash equivalent | FERAHEME Drug, For the treatment of iron deficiency anemia associated with chronic kidney disease | Efficacy and Safety of Low-Dose Ferumoxytol for Vascular Suppression in Magnetic Resonance Neurography (MRN) | 2022 |
| 2022-09-21 | Takeda Pharmaceuticals U.S.A., Inc. | $1,005 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2022 |
| 2022-09-21 | Takeda Pharmaceuticals U.S.A., Inc. | $991 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2022 |
| 2022-09-21 | Takeda Pharmaceuticals U.S.A., Inc. | $300 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2022 |
| 2022-09-21 | Takeda Pharmaceuticals U.S.A., Inc. | $250 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2022 |
| 2022-09-21 | Takeda Pharmaceuticals U.S.A., Inc. | $50 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | THIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND | 2022 |
| 2022-09-19 | SANOFI US SERVICES INC. | $6,553 | Research payment | Cash or cash equivalent | An Open Label, Two-Arm Study to Evaluate the Effect of Rilzabrutinib (PRN1008) on Safety and Disease Activity in Patient | 2022 | |
| 2022-09-15 | Ortho Development Corporation | $281 | Royalty or License | Cash or cash equivalent | Pagoda Device, ORTHOPEDIC DEVICE | 2022 | |
| 2022-09-13 | Synthes GmbH | $32,500 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-09-12 | SI-BONE, INC. | $100 | Research payment | Cash or cash equivalent | IFUSE IMPLANT Device, SACROILIAC JOINT DYSFUNCTION | SILVIA | 2022 |
| 2022-09-09 | Regeneron Pharmaceuticals, Inc. | $38,488 | Research payment | Cash or cash equivalent | TCR SEQUENCING AND TRANSCRIPTIONAL PROFILING IN HLA B27 ASSOCIATED DISEASE | 2022 | |
| 2022-09-09 | Smith+Nephew, Inc. | $5,474 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Q-FIX Device, Sports Med Hip | 2022 | |
| 2022-09-09 | Smith+Nephew, Inc. | $1,731 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | Q-FIX Device, Sports Med Hip | 2022 | |
| 2022-09-08 | Smith+Nephew, Inc. | $1,500 | Research payment | In-kind items and services | 2022 | ||
| 2022-09-07 | ABBVIE INC. | $4,342 | Research payment | Cash or cash equivalent | A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM | 2022 | |
| 2022-09-06 | Masimo Corporation | $213 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-09-06 | Masimo Corporation | $213 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-09-06 | Masimo Corporation | $213 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-09-06 | Masimo Corporation | $73 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-09-06 | Masimo Corporation | $73 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-09-06 | Masimo Corporation | $73 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-09-06 | Masimo Corporation | $30 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-09-06 | Masimo Corporation | $30 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-09-06 | Masimo Corporation | $30 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-09-06 | Masimo Corporation | $27 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-09-06 | Masimo Corporation | $27 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-09-06 | Masimo Corporation | $27 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-09-06 | Masimo Corporation | $27 | Long term medical supply or device loan | In-kind items and services | rainbow SET Device, Devices | 2022 | |
| 2022-09-04 | Smith+Nephew, Inc. | $3,756 | Debt forgiveness | Cash or cash equivalent | OR3O Dual Mobility Device, Recon Hips | 2022 | |
| 2022-09-01 | Lima USA, Inc. | $32,076 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Promade Device, Devices | 2022 | |
| 2022-09-01 | Stryker Corporation | $16,343 | Research payment | Cash or cash equivalent | TRIDENT Device, HIPS | METAL ION LEVELS IN STRYKER TRIDENT II TRITANIUM SYSTEM WITH MDM LINER, CERAMIC HEAD, AND ACCOLADE II OR SECURFIT ADVANC | 2022 |
| 2022-09-01 | ARGENX US, INC. | $337 | Research payment | Cash or cash equivalent | A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chr | 2022 | |
| 2022-08-31 | Medtronic, Inc. | $47,377 | Research payment | Cash or cash equivalent | MAZOR X SYSTEM Device, Image Guided Surgery Products | Investigator Sponsored Research | 2022 |
| 2022-08-29 | Medical Device Business Services, Inc. | $4,381 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-08-25 | Stryker Corporation | $46,342 | Research payment | Cash or cash equivalent | MAKO Device, KNEES, HIPS | MULTICENTER STUDY FOR ROBOTIC-ARM ASSISTED THA 4.0 SYSTEM WITH INTEGRATION OF PELVIC TILT AND ROM ASSESSMENTS: IMPLANT P | 2022 |
| 2022-08-25 | Stryker Corporation | $30,895 | Research payment | Cash or cash equivalent | MAKO Device, KNEES, HIPS | MULTICENTER STUDY FOR ROBOTIC-ARM ASSISTED THA 4.0 SYSTEM WITH INTEGRATION OF PELVIC TILT AND ROM ASSESSMENTS: IMPLANT P | 2022 |
| 2022-08-25 | Stryker Corporation | $3,828 | Research payment | Cash or cash equivalent | SECUR-FIT Device, HIPS | SECURFIT ADVANCED OUTCOMES STUDY | 2022 |
| 2022-08-25 | Stryker Corporation | $200 | Research payment | Cash or cash equivalent | SECUR-FIT Device, HIPS | SECURFIT ADVANCED OUTCOMES STUDY | 2022 |
| 2022-08-25 | Smith+Nephew, Inc. | $85 | Research payment | Cash or cash equivalent | JOURNEY II Device, Recon Knees | A Retro-Prospective, Non-randomized, Consecutive Series, SIngle Cohort, Multicenter Adaptive Design Study to Evaluate th | 2022 |
| 2022-08-18 | UCB SA | $45,813 | Research payment | Cash or cash equivalent | AN OPEN-LABEL EXTENSION STUDY TO EVALUATE ROZANOLIXIZUMAB IN STUDY PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS | 2022 | |
| 2022-08-18 | Stryker Corporation | $19,065 | Research payment | Cash or cash equivalent | TRITANIUM Device, HIPS | MAVRIC MAGNETIC RESONANCE IMAGING USED TO STUDY DETAILED BONE APPOSITION AND FIXATION OF THE STRYKER TRIATHLON CEMENTLES | 2022 |
| 2022-08-18 | Stryker Corporation | $12,710 | Research payment | Cash or cash equivalent | TRIATHLON Device, KNEES | MAVRIC MAGNETIC RESONANCE IMAGING USED TO STUDY DETAILED BONE APPOSITION AND FIXATION OF THE STRYKER TRIATHLON CEMENTLES | 2022 |
| 2022-08-18 | Zimmer Biomet Holdings, Inc. | $10,422 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Persona Device, Knees | 2022 | |
| 2022-08-17 | ABBVIE INC. | $68 | Research payment | Cash or cash equivalent | A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM | 2022 | |
| 2022-08-15 | Zimmer Biomet Holdings, Inc. | $3,833 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-08-15 | Zimmer Biomet Holdings, Inc. | $3,800 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-08-15 | Zimmer Biomet Holdings, Inc. | $3,707 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-08-15 | Zimmer Biomet Holdings, Inc. | $3,450 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-08-15 | Zimmer Biomet Holdings, Inc. | $2,470 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-08-15 | Zimmer Biomet Holdings, Inc. | $1,732 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-08-15 | Zimmer Biomet Holdings, Inc. | $1,332 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-08-15 | Zimmer Biomet Holdings, Inc. | $272 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-08-12 | ARGENX US, INC. | $10,000 | Research payment | Cash or cash equivalent | A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chr | 2022 | |
| 2022-08-12 | ARGENX US, INC. | $8,869 | Research payment | Cash or cash equivalent | A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chr | 2022 | |
| 2022-08-12 | SI-BONE, INC. | $4,010 | Research payment | Cash or cash equivalent | IFUSE IMPLANT Device, SACROILIAC JOINT DYSFUNCTION | SILVIA | 2022 |
| 2022-08-12 | ARGENX US, INC. | $1,000 | Research payment | Cash or cash equivalent | A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chr | 2022 | |
| 2022-08-11 | Stryker Corporation | $19,110 | Research payment | Cash or cash equivalent | MAKO Device, KNEES, HIPS | SURVIVORSHIP AND OUTCOMES OF ROBOTIC ARM ASSISTED MEDIAL UKA | 2022 |
| 2022-08-11 | Stryker Corporation | $19,110 | Research payment | Cash or cash equivalent | MAKO Device, KNEES, HIPS | SURVIVORSHIP AND OUTCOMES OF ROBOTIC ARM ASSISTED MEDIAL UKA | 2022 |
| 2022-08-10 | ABBVIE INC. | $4,373 | Research payment | Cash or cash equivalent | A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM | 2022 | |
| 2022-08-08 | E.R. Squibb & Sons, L.L.C. | $40,550 | Research payment | Cash or cash equivalent | ORENCIA Biological, Immunology | A Randomized Double-Blind, Placebo Controlled Trial of Abatacept (CTLA4-Ig) in Giant Cell Arteritis (ABAGART) | 2022 |
| 2022-08-05 | Smith+Nephew, Inc. | $67,844 | Research payment | Cash or cash equivalent | OR3O Dual Mobility Device, Recon Hips | Prospective Multi-Center study to evaluate the safety and effectiveness of the OR30 Dual Mobility system in primary and | 2022 |
| 2022-08-04 | Horizon Therapeutics plc | $202 | Research payment | Cash or cash equivalent | UPLIZNA Drug, UPLIZNA | A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED PHASE 3 STUDY WITH OPEN-LABEL PERIOD TO EVALUATE THE EFFICAC | 2022 |
| 2022-08-02 | Medical Device Business Services, Inc. | $1,014 | Research payment | Cash or cash equivalent | Kincise Device, Ortho-Hip | Prospective Randomized Multi Center Post Market study of Anterior Advantage Surgical Approach in Total Hip Arthroplasty | 2022 |
| 2022-08-01 | Lima USA, Inc. | $32,076 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Promade Device, Devices | 2022 | |
| 2022-08-01 | Zimmer Biomet Holdings, Inc. | $12,434 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-08-01 | Zimmer Biomet Holdings, Inc. | $10,805 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-08-01 | Zimmer Biomet Holdings, Inc. | $7,373 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-08-01 | Zimmer Biomet Holdings, Inc. | $6,161 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-08-01 | Zimmer Biomet Holdings, Inc. | $3,550 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-08-01 | Zimmer Biomet Holdings, Inc. | $3,483 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-08-01 | KCI USA, Inc. | $1,843 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-08-01 | KCI USA, Inc. | $616 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-07-29 | Smith+Nephew, Inc. | $135 | Research payment | Cash or cash equivalent | SPATIAL FRAME Device, Sports Med Knee | A Prospective, Multi-Center Clinical Study to Evaluate the Safety and Performance of the Fast-Fix Flex System for Menisc | 2022 |
| 2022-07-26 | NuVasive, Inc. | $99,910 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-07-26 | NuVasive, Inc. | $35,089 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-07-26 | NuVasive, Inc. | $15,000 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-07-21 | Orthofix Medical, Inc. | $27,848 | Research payment | Cash or cash equivalent | M6-C Device, Prosthesis, Intervertebral Disc | M6-C Artificial Cervical Disc IDE Post Approval Study | 2022 |
| 2022-07-21 | Orthofix Medical, Inc. | $6,585 | Research payment | Cash or cash equivalent | M6-C Device, Prosthesis, Intervertebral Disc | M6-C Artificial Cervical Disc IDE Post Approval Study | 2022 |
| 2022-07-21 | Stryker Corporation | $6,000 | Research payment | Cash or cash equivalent | INFINITY Device, TRAUMA & EXTREMITIES | INFINITY WITH ADAPTIS TECHNOLOGY TOTAL ANKLE REPLACEMENT FOLLOW-UP (ITAR2) | 2022 |
| 2022-07-15 | Medical Device Business Services, Inc. | $11,080 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-07-15 | Medical Device Business Services, Inc. | $5,687 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-07-15 | Medical Device Business Services, Inc. | $4,715 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-07-15 | Ortho Development Corporation | $636 | Royalty or License | Cash or cash equivalent | Pagoda Device, ORTHOPEDIC DEVICE | 2022 | |
| 2022-07-14 | Smith+Nephew, Inc. | $3,350 | Research payment | Cash or cash equivalent | SPATIAL FRAME Device, Sports Med Knee | A Prospective, Multi-Center Clinical Study to Evaluate the Safety and Performance of the Fast-Fix Flex System for Menisc | 2022 |
| 2022-07-14 | Janssen Biotech, Inc. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | TREMFYA Drug, Immunology | 2022 | |
| 2022-07-13 | Smith+Nephew, Inc. | $4,686 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Integra Device, Extremity, Upper | 2022 | |
| 2022-07-13 | ABBVIE INC. | $402 | Research payment | Cash or cash equivalent | A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM | 2022 | |
| 2022-07-11 | Smith+Nephew, Inc. | $5,213 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | RF20000 Device, Sports Med Resection | 2022 | |
| 2022-07-11 | Smith+Nephew, Inc. | $5,212 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | NA Device, Sports Med Resection | 2022 | |
| 2022-07-07 | AMAG Pharmaceuticals, Inc. | $8,900 | Research payment | Cash or cash equivalent | FERAHEME Drug, For the treatment of iron deficiency anemia associated with chronic kidney disease | Efficacy and Safety of Low-Dose Ferumoxytol for Vascular Suppression in Magnetic Resonance Neurography (MRN) | 2022 |
| 2022-07-07 | ABBVIE INC. | $4,571 | Research payment | Cash or cash equivalent | A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM | 2022 | |
| 2022-07-07 | Stryker Corporation | $1,500 | Research payment | Cash or cash equivalent | TRITANIUM Device, HIPS | TRIDENT II TRITANIUM OUTCOMES STUDY | 2022 |
| 2022-07-06 | Lima USA, Inc. | $38,593 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Promade Device, Devices | 2022 | |
| 2022-07-05 | Medical Device Business Services, Inc. | $6,532 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-07-05 | Apellis Pharmaceuticals, Inc. | $3,675 | Research payment | Cash or cash equivalent | MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS | 2022 | |
| 2022-07-01 | Lima USA, Inc. | $32,076 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Promade Device, Devices | 2022 | |
| 2022-06-30 | EXACTECH, INC. | $140,749 | Royalty or License | Cash or cash equivalent | TRULIANT Device, ORTHOPAEDIC | 2022 | |
| 2022-06-27 | Takeda Pharmaceuticals U.S.A., Inc. | $100 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | LONG-TERM TOLERABILITY AND SAFETY OF IMMUNE GLOBULIN INFUSION 10% (HUMAN) WITH RECOMBINANT HUMAN HYALURONIDASE (HYQVIA/H | 2022 |
| 2022-06-24 | Takeda Pharmaceuticals U.S.A., Inc. | $2,045 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | LONG-TERM TOLERABILITY AND SAFETY OF IMMUNE GLOBULIN INFUSION 10% (HUMAN) WITH RECOMBINANT HUMAN HYALURONIDASE (HYQVIA/H | 2022 |
| 2022-06-24 | Takeda Pharmaceuticals U.S.A., Inc. | $1,810 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | LONG-TERM TOLERABILITY AND SAFETY OF IMMUNE GLOBULIN INFUSION 10% (HUMAN) WITH RECOMBINANT HUMAN HYALURONIDASE (HYQVIA/H | 2022 |
| 2022-06-24 | Takeda Pharmaceuticals U.S.A., Inc. | $1,450 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | LONG-TERM TOLERABILITY AND SAFETY OF IMMUNE GLOBULIN INFUSION 10% (HUMAN) WITH RECOMBINANT HUMAN HYALURONIDASE (HYQVIA/H | 2022 |
| 2022-06-24 | Takeda Pharmaceuticals U.S.A., Inc. | $774 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | LONG-TERM TOLERABILITY AND SAFETY OF IMMUNE GLOBULIN INFUSION 10% (HUMAN) WITH RECOMBINANT HUMAN HYALURONIDASE (HYQVIA/H | 2022 |
| 2022-06-23 | Arthrex, Inc. | $9,585 | Research payment | Cash or cash equivalent | ARTHROPLASTY IMPLANTS KNEE & HIP ARTHROPLASTY TOTAL KNEE Device, ARTHROPLASTY - IMPLANTS - KNEE & HIP ARTHROPLASTY - TOTAL KNEE | SOS Total Knee Arthroplasty Registry | 2022 |
| 2022-06-22 | EXACTECH, INC. | $1,000 | Space rental or facility fees (teaching hospital only) | In-kind items and services | VANTAGE Device, ORTHOPAEDIC | 2022 | |
| 2022-06-21 | Stryker Corporation | $1,200 | Research payment | Cash or cash equivalent | CARTIVA SYNTHETIC CARTILAGE IMPLANT Device, TRAUMA & EXTREMITIES | CARTIVA GRIP2 | 2022 |
| 2022-06-20 | Smith+Nephew, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | REAL INTELLIGENCE Device, Recon Robotics | 2022 | |
| 2022-06-16 | PFIZER INC. | $12,900 | Research payment | Cash or cash equivalent | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | A LONGTERM OPENLABEL FOLLOWUP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS JIA | 2022 |
| 2022-06-16 | PFIZER INC. | $2,000 | Research payment | Cash or cash equivalent | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | A LONGTERM OPENLABEL FOLLOWUP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS JIA | 2022 |
| 2022-06-16 | Globus Medical, Inc. | $1,500 | Grant | Cash or cash equivalent | Spine Device, Spine | 2022 | |
| 2022-06-15 | Ortho Development Corporation | $830 | Royalty or License | Cash or cash equivalent | Pagoda Device, ORTHOPEDIC DEVICE | 2022 | |
| 2022-06-10 | Medical Device Business Services, Inc. | $3,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-06-09 | ABBVIE INC. | $6,412 | Research payment | Cash or cash equivalent | A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM | 2022 | |
| 2022-06-09 | Smith+Nephew, Inc. | $4,506 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | REAL INTELLIGENCE Device, Recon Robotics | 2022 | |
| 2022-06-09 | Medical Device Business Services, Inc. | $4,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2022 | ||
| 2022-06-09 | Smith+Nephew, Inc. | $2,687 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | REAL INTELLIGENCE Device, Recon Robotics | 2022 | |
| 2022-06-09 | E.R. Squibb & Sons, L.L.C. | $1,591 | Research payment | Cash or cash equivalent | ORENCIA Biological, Immunology | Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy | 2022 |
| 2022-06-06 | Medtronic, Inc. | $6,351 | Research payment | Cash or cash equivalent | MAZOR X SYSTEM Device, Image Guided Surgery Products | Investigator Sponsored Research | 2022 |
| 2022-06-06 | Smith+Nephew, Inc. | $665 | Research payment | Cash or cash equivalent | SPATIAL FRAME Device, Sports Med Knee | A Prospective, Multi-Center Clinical Study to Evaluate the Safety and Performance of the Fast-Fix Flex System for Menisc | 2022 |
| 2022-06-06 | Smith+Nephew, Inc. | $67 | Research payment | Cash or cash equivalent | SPATIAL FRAME Device, Sports Med Knee | A Prospective, Multi-Center Clinical Study to Evaluate the Safety and Performance of the Fast-Fix Flex System for Menisc | 2022 |
| 2022-06-02 | PFIZER INC. | $2,000 | Research payment | Cash or cash equivalent | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | EFFICACY SAFETY TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS | 2022 |
The latest 200 records of 327.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In New York, NY, county Kings County, NY, state New York; placed by its city name.
| Measure | Place (city or town) New York, NY | County Kings County, NY | State New York |
|---|---|---|---|
| Population B01003 | 8,483,844 | 2,631,580 | 19,852,366 |
| Population, 2020 census P1 | 8,804,190 | 2,736,074 | 20,201,249 |
| Median age B01002 | 38.2 | 36.5 | 39.8 |
| Under 18 B01001 | 20.2% | 22.2% | 20.5% |
| 65 and over B01001 | 16.6% | 15.5% | 17.9% |
| Households B11001 | 3,334,088 | 1,009,927 | 7,722,646 |
| Foreign born B05002 | 36.6% | 35.3% | 22.8% |
| Median household income B19013 | $80,483 | $80,263 | $85,974 |
| Median family income B19113 | $91,707 | $88,947 | $106,873 |
| Per capita income B19301 | $51,844 | $47,575 | $50,712 |
| Poverty rate B17001 | 17.9% | 19.1% | 14.0% |
| Unemployment rate B23025 | 8.0% | 7.9% | 6.4% |
| Civilian labor force B23025 | 4,392,297 | 1,353,361 | 10,171,766 |
| Mean commute (minutes) B08013 | 40.3 | 41.7 | 32.6 |
| Bachelor's degree or higher B15003 | 41.6% | 42.1% | 40.2% |
| Housing units B25001 | 3,678,486 | 1,100,772 | 8,585,241 |
| Owner-occupied B25003 | 32.8% | 29.5% | 54.3% |
| Renters B25003 | 67.2% | 70.5% | 45.7% |
| Median home value B25077 | $777,600 | $905,000 | $423,800 |
| Median gross rent B25064 | $1,821 | $1,833 | $1,621 |
| White, not Hispanic B03002 | 31.0% | 36.1% | 52.8% |
| Black B03002 | 20.4% | 26.6% | 13.4% |
| Hispanic or Latino B03002 | 28.5% | 19.0% | 19.8% |
| Asian B03002 | 14.6% | 12.1% | 9.0% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in New York, NY.
Comments